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CPT-11, a new semisynthetic derivative of camptothecin, is
active in a number of tumor types in the clinic, including colon
cancer. CPT-11 is a drug that is converted into the active
metabolite SN-38 by a carboxylesterase. Experiments were
performed to obtain more insight in the cellular characteris-
tics in 5 unselected human colon-cancer cell lines that ac-
count for the differential sensitivity to CPT-11 and SN-38. In
vitro, the sensitivity to CPT-11 and SN-38 was highest in
LS174T and COLO 320 cells, intermediate in SW1398 cells
and lowest in COLO 205 and WiDr cells. SN-38 was 130 to
570 times more active than CPT-11. CPT-11 induced com-
plete remissions in 6 out of 12 COLO 320 tumors grown as
subcutaneous xenografts, but was not effective in WiDr
tumors. The cellular carboxylesterase activity did not relate
to the sensitivity to CPT-11. The enzyme activity was higher
in normal mouse tissues, i.e., serum and liver, than in COLO
320 orWiDr xenografts, indicating that tumor carboxylester-
ase is ofminor importance for CPT-11 efficacy. The topoisom-
erase-I mRNA expression in tumor cells was not predictive of
the antiproliferative effects of CPT-11 or SN-38. We ob-
served a positive relationship between the DNA topoisomer-
ase-I activity and the cellular sensitivity to carboxylesterase-
activated CPT-11 (r 5 0.75, pF 0.1) as well as to SN-38
(r 5 0.89, pF 0.05). The higher topoisomerase-I activity in
COLO 320 cells and tumors when compared with that in
WiDr cells and tumors reflected the differences in sensitivity
to the drug(s). In conclusion, the DNA topoisomerase-I
activity was the best determinant for CPT-11/SN-38 sensitiv-
ity in this panel of unselected human colon-cancer cell lines.
Int. J. Cancer, 70:335–340, 1997.
r 1997 Wiley-Liss, Inc.
Camptothecin is a naturally occurring anti-tumor agent, which
was isolated from the Chinese tree Camptotheca acuminata. It has
a broad spectrum of activity against experimental animal tumor
models in the ascites as well as the solid form. Its clinical
development has been hampered by severe side-effects, consisting
of unpredictable hemorrhagic cystitis, diarrhea and myelosuppres-
sion, and because of its poor solubility. More recent studies have
revealed that camptothecin inhibits the resealing of single-strand
DNA breaks mediated by topoisomerase I, which was identified as
the specific intracellular enzyme target for the drug. Camptothecin
stabilizes cleavable complexes, resulting in single-strand DNA
breaks that cannot be religated in the presence of the drug. The
cytotoxicity of camptothecin occurs mainly in the S-phase of the
cell cycle (reviewed by Slichenmyer et al., 1993; Creemers et al.,
1994).
With the increasing knowledge of the function of topoisomerase
I and the potent cytotoxic activity of camptothecin, semi-synthetic
analogues were developed aiming at better water solubility and
fewer side-effects. 7-Ethyl-10-(4-[1-piperidino]-1-piperidino)car-
bonyloxycamptothecin (CPT-11) is a camptothecin analogue which
was shown to have excellent anti-tumor activity against a variety of
human tumor xenografts, when administered by the intravenous,
intraperitoneal or oral route (Kawato et al., 1991; Houghton et al.,
1995). The drug was only marginally active in vitro and it was
discovered that metabolic activation of CPT-11 by a carboxylester-
ase was essential for its activity. The active metabolite was
identified to be 7-ethyl-10-hydroxycamptothecin (SN-38) (Tsuji et
al., 1991). Clinical studies have shown that CPT-11 has significant
activity against a broad range of tumor types, including colon
cancer. Moreover, CPT-11 has less unpredictable side-effects than
the parent compound (Slichenmyer et al., 1993; Creemers et al.,
1994).
Although much information is available concerning the cyto-
toxic mechanism of camptothecins, we performed experiments to
gain more insight into the differences between tumor cells that
account for the differences in sensitivity to CPT-11. Therefore, an
in vitro analysis of 5 human colon-cancer cell lines was carried out
to determine the anti-proliferative effects of CPT-11 and SN-38.
CPT-11 activity was also studied in nude mice bearing subcutane-
ous human colon-cancer xenografts grown from 2 of these cell
lines. We investigated the role of endogenous carboxylesterase as
well as the addition of exogenous carboxylesterase in the cellular
sensitivity to CPT-11. Carboxylesterase activity was also assessed
in normal mouse organs and in human tumor xenografts to identify
the sites primarily involved in CPT-11 activation. The topoisomer-
ase-I gene expression and activity were also determined. The
various cellular characteristics were analysed for the possible
presence of a relationship with the in vitro and in vivo sensitivity to
the drugs.
MATERIAL AND METHODS
Reagents
CPT-11 (Irinotecan) as a solution of 20 mg/ml and SN-38 as a
powder were kindly provided by Rhoˆne-Poulenc Rorer (Vitry sur
Seine, France). SN-38 was dissolved in DMSO to a final concentra-
tion of 10 mM. Carboxylesterase (EC 3.1.1.1), isolated from
porcine liver, was purchased from Sigma (Zwijndrecht, The
Netherlands). Drugs were further diluted in tissue culture media
when investigated for their anti-proliferative effects in vitro.
Cell lines and xenografts
The human colon-cancer cell lines COLO 205, COLO 320,
SW1398, WiDr and LS174T were cultured in Dulbecco’s modified
Eagle’s medium (GIBCO, Breda, The Netherlands), 10% heat-
inactivated FCS (Sebak,Aidenbach, Germany), 50 IU/ml penicillin
and 50 µg/ml streptomycin (Flow, Irvine, UK) in an incubator with
a humified atmosphere containing 5% CO2 at 37°C (Jansen et al.,
1995). All cell lines were free from Mycoplasma contamination as
tested regularly with the Mycoplasma T.C. rapid detection system
with a 3H-labeled DNA probe from Gene-Probe (San Diego, CA).
Female nude mice (Hsd: athymic nude-nu) were purchased at the
age of 6 weeks (Harlan CPB, Zeist, The Netherlands). The animals
were maintained in cages with paper filter covers under controlled
atmospheric conditions. Cages, covers, bedding, food and water
were changed and sterilized weekly. Animals were handled in a
sterile manner in a laminar down-flow hood. The COLO 320 and
WiDr xenografts were established from cell lines grown in
tissue-culture medium. Mice were inoculated subcutaneously with
1 3 107 cells in both flanks. The solid tumors arising at the
inoculation site (passage 1) were transferred as tissue fragments
with a diameter of 2–3 mm through a small skin incision into both
flanks of 8- to 10-week-old mice.
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In vitro sensitivity
For growth-inhibition experiments, colon-cancer cells were
plated in 96-well microtiter plates (5,000 cells/well) as described
(Jansen et al., 1995). Briefly, after 24 hr cells were exposed
continuously for 96 hr to varying concentrations of the drugs
CPT-11, SN-38, or CPT-11, in combination with an excess of
carboxylesterase (1 µg/ml). The anti-proliferative effects were
determined by the MTT assay. The cells were stained for 4 hr with
the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,6-
dimethyl-morpholino)-2,5-diphenyl-tetrazolium bromide; Sigma,
St Louis, MO) in PBS (0.4 mg/ml). MTT was reduced to a
dark-colored formazan by living cells only, as measured on a
LabsystemsMultiscan Bichromatic plate reader (Helsinki, Finland)
at 540 nm. The results were expressed as the IC50, which is the
concentration of the drug(s) inducing a 50% inhibition of cell
growth of treated cells when compared to the growth of control
cells. In control cultures, cell growth was exponential during the
assay period.All concentrations were tested in 4 replicate wells and
each experiment was performed at least 3 times.
In vivo sensitivity
Treatment experiments in mice bearing subcutaneous colon-
cancer xenografts were carried out in passage 2 or higher. The
tumors were measured twice a week in 3 dimensions with Vernier
calipers. The volume was calculated by the equation length 3
width 3 thickness 3 0.5, and expressed in mm3. At the start of
treatment (designated as day 0), groups of 5 to 6 tumor-bearing
mice were formed to provide a mean tumor volume of approxi-
mately 150 mm3 in each group (Boven et al., 1988).
For in vivo use, CPT-11 was diluted in NaCl 0.9% to 2 mg/ml
and 20 mg/kg were administered intraperitoneally on days 0, 1, 2,
3, 4. The selected dose of CPT-11 in the daily 35 schedule was the
maximum tolerated dose as established in non-tumor-bearing nude
mice. This maximum tolerated dose was based on the occurrence of
a mean weight loss of approximately 10% of the initial weight
within the first 2 weeks after the start of the treatment. For the
evaluation of drug efficacy, the tumor volume was expressed by the
formula VT/V0, where VT is the volume on any given day and V0 is
the volume on day 0. The ratio of the mean relative volume of
treated tumors over that of control tumors multiplied by 100%
(T/C%) was assessed on each day of measurement (Boven et al.,
1988). Anti-tumor effects were expressed as the percentage of
growth inhibition (100%-T/C%).
Carboxylesterase activity
The determination of the carboxylesterase activity in cells,
mouse organs or xenografts was adapted from an assay based on
the conversion of colorless para-nitrophenylacetate (pNPA) to
yellow para-nitrophenol (Tsuji et al., 1991). Cells (1 3 107) were
lysed on ice in 1 ml 20 mM TRIS-HCl buffer pH 7.5 for 1 hr,
followed by freeze-thawing. Organs and tumors were weighed and
20 mM TRIS-HCl buffer were added. Tissues were homogenized
thoroughly with a Polytron homogenizer and lysed on ice for 1 hr.
Cells and homogenates were then centrifuged at 4°C for 30 min at
14,000 g, then the supernatants were centrifuged again and stored
at 220°C. Before analysis, samples were diluted in TRIS-HCl
buffer to obtain measurable carboxylesterase activity. The diluted
sample (180 µl) was transferred to a 96-well microtiter plate and
the reaction was started by adding 20 µl 10 mM pNPA (Sigma) as a
substrate. After an incubation period of 10 min at 37°C, the
extinction of the liberated para-nitrophenol was monitored at 405
nm on the Labstems Multiscan Bichromatic plate reader. To correct
the data for the spontaneous conversion of the substrate, 20 µl 10
mM pNPA was added to 180 µl TRIS-HCl buffer. The enzyme
activity was expressed in units, one unit of enzyme activity being 1
µmol liberated para-nitrophenol per min at 37°C. Three batches of
each cell line and 3 different specimens of the various tissues were
tested. The samples were tested in 3 replicate wells and each
experiment was performed 3 times.
Topoisomerase-I expression
Total cellular RNA was isolated from exponentially growing
cells or from frozen xenograft tissue sections with RNAzol B
(Campro Scientific, Veenendaal, The Netherlands). [a-32P]labeled
RNA complementary to the topoisomerase-I cDNA 703-bp se-
quence (nucleotides 835-1538) (Juan et al., 1988), inserted into
pGEM3, was transcribed from FokI-linearized DNA using T7
polymerase. RNase protection was carried out as described (Giac-
cone et al., 1995). In all experiments, a probe for g-actin was
included to control for RNA loading. The hybridized probe was
visualized after gel electrophoresis through a denaturing 6%
acrylamide gel. For autoradiography, the gel was exposed at
270°C to a Kodak BIOMAX MR film for 3 days. The amount of
topoisomerase-I mRNA relative to the amount of g-actin was
calculated by densitometric scanning of autoradiograms. Topoisom-
erase-I expression was determined at least 3 times in each cell line
and at least twice in 3 separate tumors of a cell line.
Topoisomerase-I activity
DNA topoisomerase-I activity was determined using the DNA
relaxation assay (Liu and Miller, 1981). Briefly, at least 1 3 107
human colon-cancer cells or 50–100 mg of fresh xenograft tissue
were lysed for 10 min on ice in nuclear buffer supplemented with
Triton-X, 1 nM phenylmethanesulfonylfluoride (PMSF) and 0.2
µM dithiothreitol (DTT). Nuclear enzymes were extracted from
cell nuclei by incubation with nuclear buffer containing 0.4 M
NaCl for 30 min on ice. The enzyme solution was diluted with an
equal volume of 87% glycerol and stored at 270°C for a maximum
of one week. Topoisomerase-I activity was determined by measur-
ing the relaxation of supercoiled pBR329 plasmid DNA by
incubation of serial dilutions of the nuclear extracts at 37°C for 30
min. Supercoiled and relaxed DNAwere separated in a 1% agarose
gel by electrophoresis and visualized by ethidium bromide stain-
ing. The enzyme activity was expressed in units. One unit of
enzyme activity was defined as the total relaxation of 1 µg pBR329
plasmid DNA per min at 37°C. DNA topoisomerase-I activity was
measured at least 4 times in each cell line and at least 3 times in 3
separate tumors of a cell line.
Statistics
Linear regression analysis was used to analyze the sensitivity of
the cells in relation to the cellular carboxylesterase activity,
topoisomerase-I mRNA expression and DNA topoisomerase-I
activity.
RESULTS
In vitro sensitivity
The anti-proliferative effects of CPT-11 without or with the
addition of carboxylesterase and of SN-38 in the 5 human
colon-cancer cell lines, expressed as IC50 values, are summarized in
Table I. The sensitivity to CPT-11 alone varied between 2.5 and 6.1
µM. The addition of carboxylesterase in an excess of 1 µg/ml to
CPT-11 resulted in IC50 values between 0.021 µM and 0.21 µM
which were 30 to 150 times lower than those measured for CPT-11
alone. The sensitivity to CPT-11 plus carboxylesterase was highest
in LS174T and COLO 320 cells, intermediate in SW1398 cells and
lowest in COLO 205 and WiDr cells. The anti-proliferative effects
of the active metabolite SN-38 showed IC50 values between 5.6 and
38 nM, 130 to 570 times lower than those measured for CPT-11
alone. The sensitivity to SN-38 was highest in LS174T and COLO
320 cells, intermediate in SW1398 cells and lowest in COLO 205
and WiDr cells. The degree of sensitivity to CPT-11 and to SN-38
was similar for the 5 colon-cancer cell lines.
In vivo sensitivity
The WiDr and COLO 320 cell lines were selected for in vivo
experiments, because of their difference in sensitivity to SN-38. In
vitro, WiDr cells were approximately 7-fold less sensitive than
COLO 320 cells. In the nude mouse, the volume doubling times
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(TD) of the COLO 320 and WiDr xenografts were 15 and 7.5 days,
respectively. In COLO 320 xenografts, CPT-11 induced a maxi-
mum growth inhibition of 92% on day 42 (Fig. 1). Six out of 12
animals with COLO 320 tumors showed a complete remission,
which was sustained beyond the end of the experiment (day 105).
Regrowth in the 6 other mice occurred after day 60 of the
experiment. Because of the low percentage of growth inhibition
(52%) in WiDr xenografts, CPT-11 activity testing was repeated
twice in these tumors. Maximum growth inhibition was even lower,
being 21% and 11%, respectively. In WiDr tumors no complete
remissions were observed. The weight loss (6SD) induced by
CPT-11 did not differ between mice bearing WiDr and COLO 320
xenografts and was 4.8% (62.8%) and 7.3% (65.9%), respec-
tively.
Carboxylesterase activity
Using pNPA as a substrate to determine carboxylesterase activ-
ity, we found a slight variation in endogenous carboxylesterase
activity among the different cell lines (Fig. 2). LS174T and WiDr
cells showed the highest enzyme activity of 65 and 64 mU/mg
protein, respectively. COLO 205 cells had an intermediate activity
of 48 mU/mg protein, whereas the enzyme activity in SW1398 and
COLO 320 cells was relatively low, amounting to 38 and 29
mU/mg protein, respectively. The protein contents of the various
colon-cancer cell lines differed substantially, for which reason we
also estimated the carboxylesterase activity per 107 cells. The
carboxylesterase activity was lowest in COLO 320 cells (23
mU/107 cells), and highest in COLO 205 andWiDr cells (42 and 54
mU/107 cells, respectively). Only in the case of LS174T cells was
the carboxylesterase activity expressed per 107 cells lower than
when expressed per mg protein. The endogenous carboxylesterase
activity, expressed either per mg protein or per 107 cells, was not
related to CPT-11 sensitivity (r 5 0.35; p , 0.5 and r 5 0.33;
p , 0.5, respectively). Remarkably, the level of carboxylesterase
activity found in WiDr cells (64 mU/mg) was higher than that in
COLO 320 cells (29 mU/mg), despite COLO 320 cells showing a
higher sensitivity to CPT-11 than WiDr cells. FCS contained ,10
mU/mg protein carboxylesterase activity.
The carboxylesterase activity was also determined in COLO 320
and WiDr xenografts and in normal mouse organs (Fig. 2). The
enzyme activity in COLO 320 (45 mU/mg) and WiDr (90 mU/mg)
xenografts reflected the degree of activity in the COLO 320 (29
mU/mg) and WiDr (64 mU/mg) cell lines. The 1.4-fold higher
enzyme activity in tumor tissue may be due to the presence of
minimal amounts of mouse serum in the assay, as mouse serum
contained 150 mU/mg protein carboxylesterase activity. Normal
organs contained a higher carboxylesterase activity than mouse
serum; this activity was highest in small intestine, stomach and
liver, being 900, 675 and 525 mU/mg, respectively. Kidney and
colon expressed a lower activity, i.e. 300 and 275 mU/mg,
respectively.
DNA topoisomerase-I gene expression and activity
The expected 84-bp transcript size for topoisomerase-I mRNA
was detected in all cell lines (Table II). Small variations were seen
among the 5 cell lines, in contrast with the wider range of
sensitivity to CPT-11 plus carboxylesterase or to SN-38. Topoisom-
erase-I mRNA expression did not correlate either with the sensitiv-
ity to CPT-11 plus carboxylesterase (r 5 0.34; p , 0.5) or to SN-38
(r 5 0.36; p , 0.5).
Topoisomerase-I activity was measured in nuclear extracts from
cell lines by ATP-independent relaxation of supercoiled DNA. The
highest relaxation activity was found in LS174T cells and amounted
to 113 mU/µg nuclear protein (Table II). The other cell lines
showed a lower DNA topoisomerase-I activity, between 38 and 85
mU/µg nuclear protein, the enzyme activity of which was lowest in
WiDr cells. Figure 3 demonstrates that a low IC50 value for CPT-11
plus carboxylesterase or for SN-38 was associated with a high
DNA topoisomerase-I activity. A positive relationship was present
between the sensitivity to CPT-11 plus carboxylesterase and the
extent of DNA topoisomerase-I activity (r 5 0.75; p , 0.1). The
relationship between the sensitivity to SN-38 and the enzyme
activity was even better and statistically significant (r 5 0.89;
p , 0.05).
The DNA topoisomerase-I activity was also determined in
COLO 320 and WiDr xenografts. The relaxation assay indicated
that the DNA topoisomerase-I activity was significantly higher in
COLO 320 xenografts than inWiDr xenografts and amounted to 77
and 50 mU/µg protein, respectively. The topoisomerase-I activity in
COLO 320 and WiDr xenograft tissue was comparable with that in
the same cells in vitro.
DISCUSSION
The cellular determinants for sensitivity to topoisomerase-I
inhibitors, and CPT-11 in particular, are only partially known.
Topoisomerase I is the intracellular target for camptothecins and
the sensitivity to these compounds may be related to the topoisom-
erase-I gene expression, topoisomerase-I protein levels, the activity
of the enzyme, and/or the formation of drug-stabilized cleavable
complexes. Other cellular factors of importance for sensitivity to
camptothecins may be the uptake of the drugs, the cell-cycle
distribution and, for CPT-11, the endogenous carboxylesterase
activity. In our study in 5 human colon-cancer cell lines and 2
human colon-cancer xenografts, we found the DNA topoisomer-
ase-I activity to be a better determinant for CPT-11 and SN-38
sensitivity than the carboxylesterase activity or the topoisomerase-I
mRNA expression.
A carboxylesterase is required for the conversion of CPT-11 into
the active metabolite SN-38 to exert its cytotoxicity (Tsuji et al.,
1991). The anti-proliferative effects of CPT-11 in vitro are,
therefore, most likely caused by its conversion into SN-38, either
by cellular (endogenous) carboxylesterase or by carboxylesterase
present in FCS (,10 mU/mg protein). Addition of an excess of
(exogenous) carboxylesterase increased the anti-proliferative ef-
fects of CPT-11 30- to 150-fold in the 5 colon-cancer cell lines
tested. This demonstrates that the amount of cellular carboxylester-
ase is not sufficient for inducing maximal CPT-11 activation. The
anti-proliferative effects of CPT-11 plus an excess of carboxylester-
ase were less marked, however, than those of SN-38, but the degree
of sensitivity was similar in the 5 colon-cancer cell lines tested. The
activation of CPT-11 by exogenous carboxylesterase in vitro may
not have been complete. A possible explanation may be the action
of the enzyme under suboptimal conditions, as a result of which the
various nutrients present in the tissue-culture medium might
TABLE I – ANTIPROLIFERATIVE EFFECTS OF CPT-11 WITHOUT/WITH CARBOXYLESTERASEAND OF SN-38 IN HUMAN
COLON-CANCER CELL LINESAFTER DRUG EXPOSURE FOR 96 HR
Cell line CPT-111 M (6SD) CPT-11 1 CE1 M (6SD) SN-381 M (6SD)
COLO 205 4.3 (60.9) 3 1026 5.7 (62.1) 3 1028 2.2 (61.8) 3 1028
COLO 320 3.2 (60.7) 3 1026 2.1 (62.0) 3 1028 5.6 (64.8) 3 1029
SW1398 2.8 (61.1) 3 1026 4.8 (66.1) 3 1028 1.2 (61.5) 3 1028
WiDr 6.1 (63.3) 3 1026 2.1 (62.7) 3 1027 3.8 (62.6) 3 1028
LS174T 2.5 (62.1) 3 1026 3.4 (63.3) 3 1028 6.7 (65.9) 3 1029
1Mean in M (6SD) of at least 3 separate experiments.
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interfere with the conversion to SN-38. In addition, it is uncertain
whether the carboxylesterase extract from porcine liver, which we
used in our experiments, is a good substitute for the endogenous
carboxylesterase activity that converts CPT-11 in other species.
One should also consider the possibility that CPT-11 activation in
vitro at neutral pH will partly generate the less active open ring
form of SN-38 (Rivory and Robert, 1995). An interesting finding,
in pharmacokinetic studies in patients, was that only a proportion
of the CPT-11 administered was converted into SN-38 (Rothenberg
et al., 1993; Abigerges et al., 1995). By comparing the area under
the curve concentrations for total CPT-11 and SN-38 in these
patients, the amount of SN-38 measured varied between 3% and
8% of that of the parent compound.
As CPT-11 is converted into SN-38 by a carboxylesterase, a
correlation might be expected between the carboxylesterase activ-
ity in tumor cells and the sensitivity to CPT-11. In our study we
found no relation between the intracellular enzyme activity and
CPT-11 sensitivity. As an illustration, WiDr cells were less
sensitive to CPT-11 than the more sensitive COLO 320 cells that
contained a lower level of enzyme activity. Our cell lines were not
selected for resistance to camptothecins and exhibited natural
differences in sensitivity to these compounds. However, a role for
cellular carboxylesterase has been described in a number of cell
lines with acquired resistance to CPT-11, such as PC-7/CPT cells
with reduced capacity to form SN-38 (Kanzawa et al., 1990) or
HAC2/0.1 cells with decreased activity of the enzyme (Ogasawara
et al., 1995).
Although there is local activation of CPT-11 in tumor tissue,
carboxylesterases are ubiquitous in all vertebrates and conversion
of CPT-11 is likely to occur in the major pharmacological sites, i.e.
blood and liver. We found that mouse serum and liver contained
higher enzyme activity than human colon-cancer xenografts. This
appears to indicate that the low endogenous carboxylesterase
activity present in colon-cancer tissue has only a minor influence
on CPT-11 efficacy. Further support for this hypothesis has been
provided by Kawato et al. (1991), demonstrating an almost equal
conversion of CPT-11 into SN-38 by homogenates of 4 different
human tumor xenografts, whereas the sensitivity of these tumors
to CPT-11 in vivo was independent of their ability to produce
SN-38.
FIGURE 1 – Growth curves of COLO 320 and WiDr xenografts in
nude mice. The mean relative volumes of untreated tumors (s) and of
tumors treated with CPT-11 20 mg/kg i.p. daily 35 (d) are shown.
Arrows indicate the days of treatment and bars represent SEM.
FIGURE 2 – (A) Endogenous carboxylesterase activity (mean 6 SD)
in various human colon cancer cell lines expressed in mU/mg protein.
(B) Endogenous carboxylesterase activity (mean 6 SD) in xenograft
tissue and normal mouse organs expressed in mU/mg protein.
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A relationship may be present between topoisomerase-I gene
expression and sensitivity to CPT-11 or to SN-38.Adecreased gene
expression has indeed been found in camptothecin-resistant cell
lines selected after exposure to the drug (Woessner et al., 1992). In
our panel of unselected human colon-cancer cell lines, we found no
correlation between the extent of topoisomerase-I mRNA expres-
sion and the anti-proliferative effects of CPT-11 without or with an
excess of carboxylesterase or of SN-38. Similar observations have
been described in another panel of 7 unselected human colon-
cancer cell lines (Goldwasser et al., 1995) and in 7 unselected cell
lines of different tumor origin (Perego et al., 1994).
Reduced levels of cellular topoisomerase-I protein measured by
Western blotting in nuclear extracts have been reported to relate
with a lower sensitivity to camptothecin (Sugimoto et al., 1990;
Chang et al., 1992), and can be associated with decreased
topoisomerase-I mRNA expression (Woessner et al., 1992). In
unselected cell lines, however, Goldwasser et al. (1995) have
demonstrated that there was no relation between topoisomerase-I
protein expression and camptothecin sensitivity. Apart from West-
ern blotting, one can also use a monoclonal antibody to detect the
topoisomerase-I protein by immunocyto- or histochemistry (Negri
et al., 1992). In our hands, this method was less useful for
quantification of the protein contents.
Our study indicated a positive correlation between the DNA
topoisomerase-I activity and the cellular sensitivity to activated
CPT-11 as well as to SN-38. The more sensitive cells showed a
higher enzyme activity, and this was also found in the human
colon-cancer xenografts. A reduction in the topoisomerase-I activ-
ity has also been described in a number of cell lines with acquired
drug resistance to camptothecins (Chang et al., 1992; Woessner et
al., 1992).
The 2-fold difference in topoisomerase-I activity between COLO
320 and WiDr xenografts would probably not explain the much
higher sensitivity of COLO 320 tumors to CPT-11 in vivo. This
suggests that other cell-specific factors, e.g. proliferation rate,
cell-cycle distribution, SN-38 uptake or drug-resistance mecha-
nisms, might contribute to the sensitivity to CPT-11. Non-
proliferating tumor cells are generally less sensitive to campto-
thecins, since DNA replication is essential for the cytotoxicity of
these topoisomerase-I inhibitors (Gallo et al., 1971). Campto-
thecins are specifically cytotoxic to S-phase cells, although cellular
levels of topoisomerase I are relatively constant during the phases
of the cell cycle (Heck et al., 1988). The growth rate of the
xenografts, however, did not account for the difference in CPT-11
sensitivity as COLO 320 tumors had a slow TD of 15 days when
compared with the TD of 7.5 days in WiDr tumors. We cannot be
sure whether or not the uptake of CPT-11 or SN-38 in the tumor
cells played a role in the different drug effects. Earlier observations
have revealed that the uptake of camptothecins in vitro was
unaltered in cells that differed in sensitivity (Kanzawa et al., 1990;
Goldwasser et al., 1995). Some studies have suggested a role for
P-glycoprotein (Pgp) in resistance against camptothecins. For
example, Mattern et al. (1993) have shown that the expression of
Pgp may affect the cytotoxicity of topotecan, 9-aminocamptothe-
cin, CPT-11 and SN-38 in vitro. In vivo, however, the various
camptothecins were equally effective against the multidrug-
resistant tumors and the parental tumors. Unlike WiDr cells, the
COLO 320 cells express Pgp (Jansen et al., 1995), which does not
explain the difference in sensitivity to CPT-11.
Although we found a positive correlation between the DNA
topoisomerase-I activity and cellular sensitivity to activated CPT-11
and SN-38, the correlation may even be stronger when measuring
drug-induced topoisomerase-I-cleavable complexes. The forma-
tion of stable complexes is the initial step leading to drug-induced
cell death (Tanizawa et al., 1995). Rubin et al. (1994) and Fujimori
et al. (1995) have described cell lines with acquired resistance to
camptothecins containing functional topoisomerase I, but with
reduced formation of drug-induced topoisomerase-I-cleavable com-
plexes. Goldwasser et al. (1995) have indeed reported a positive
correlation between camptothecin-induced topoisomerase-I-cleav-
able complexes and camptothecin sensitivity. Whether this assay
will better explain the difference in in vivo sensitivity between
COLO 320 and WiDr tumors remains to be investigated. The
technique, however, is cumbersome and most reliable when
cellular DNA is labeled. It can, therefore, not be easily transferred
to the clinic (Goldwasser et al., 1995).
In conclusion, of the various cellular characteristics responsible
for sensitivity to CPT-11, we found the activity of DNA topoisom-
erase I to correlate best in this panel of unselected colon-cancer cell
lines. The usefulness of this assay as a potential predictive test in
the daily management of cancer patients to be treated with CPT-11
will be the subject of further studies.
TABLE II – TOPOISOMERASE-I EXPRESSIONANDACTIVITY IN HUMAN COLON-CANCER CELL LINES
Material
Topo-I
Expression1
Mean (6SD)
Topo-I activity2
Median (range) Mean (6SD)
Cell line
COLO 205 1.48 (60.63) 47 (34–95) 55 (625)
COLO 320 1.00 85 (56–91) 79 (616)
SW1398 0.86 (60.30) 63 (47–95) 66 (618)
WiDr 1.36 (60.46) 38 (30–61) 41 (612)
LS174T 1.48 (60.42) 113 (55–170) 111 (646)
Xenografts
COLO 320 0.97 (60.04) 77 (61–96) 78 (618)
WiDr 0.79 (60.18) 50 (38–65) 53 (68)
1Topoisomerase-I gene expression relative to the g-actin gene measured in at least 3 different samples.
Values are expressed relative to COLO 320 cells or to one of the 3 COLO 320 xeno-
grafts.–2Topoisomerase-I activity (mU/µg) measured in at least 4 different samples.
FIGURE 3 – Linear regression between the topoisomerase-I activity
(mU/µg) and the IC50 values of CPT-11 (d, r 5 0.75; p , 0.1) or of
SN-38 (s, r 5 0.89; p , 0.05) in the 5 human colon-cancer cell lines.
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